Health
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society of Dermatologic Surgery (ASDS) Annual Meeting, November 13-16, 2025, in Chicago, Illinois. Oral and video poster presentations, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering scientific research and innovation.
About this update from Abbvie Inc.
[{"type":"text","content":"- A total of 17 abstracts, including three accepted for presentation in the Cosmetic "Top Ten" Session, underscore Allergan Aesthetics' global industry leadership across multiple aesthetic categories","length":218,"tagName":"p"},{"type":"text","content":"- Oral abstract presentations include Phase 3 clinical study results for first-in-class botulinum neurotoxin serotype E (trenibotulinumtoxinE) and results from a Phase 4 study evaluating natural outcomes and patient satisfaction in a diverse population following use of 64 units of BOTOX® Cosmetic (onabotulinumtoxinA) for treatment of upper facial lines","length":369,"tagName":"p"},{"type":"text","content":"- Expert panel discussion explores new Hyaluronic Acid Injectable Fillers Report, along with current use, facts, and real-world satisfaction data ","length":145,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., Nov. 12, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced it will present data highlighting efficacy, safety and patient-reported outcomes across its portfolio during the 2025 American Society of Dermatologic Surgery (ASDS) Annual Meeting, November 13-16, 2025, in Chicago, Illinois. Oral and video poster presentations, along with expert panels and symposiums, collectively demonstrate Allergan Aesthetics' pioneering scientific research and innovation.","length":520,"tagName":"p"},{"type":"text","content":""Allergan Aesthetics leads the industry by consistently delivering clinically differentiated products to patients and providers through new indications and expanded uses for existing treatments, as well as novel investigational assets that meet the evolving needs of the market," said John Maltman, vice president, global aesthetics medical affairs, Allergan Aesthetics. "The scientific and clinical data reported at this year's congress demonstrate how we continue to drive evidence-based innovation across our robust product portfolio, with the goal of improving the standard of care and personalized outcomes for all."","length":645,"tagName":"p"},{"type":"text","content":"Three abstracts were accepted for live presentation in the Cosmetic Oral Abstract Presentations: Top Ten Session where primary authors will present in-person on Thursday, November 13, at 10:45...